Swiss drugmaker Roche said on Thursday it would study its anti-inflammation drug Actemra mixed with Gilead Sciences Inc's remdesivir in hospitalised patients with severe COVID-19 pneumonia in a global trial of around 450 patients.
from Reuters: Health News https://ift.tt/2M6u4II
No comments:
Post a Comment